Catequentinib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Catequentinib
- Molecular weight
- 407.45
- Structure (SMILES)
- COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
- al 3818
- AL 3818
- Al-3818
- AL-3818
- al3818
- AL3818
- AL3818 Capsule
- altn
- ALTN
- anlotinib
- Anlotinib
- catequentinib
- Catequentinib
- catequentinib [INN]
- CATEQUENTINIB [USAN]
- Catequentinib [WHO-DD]
- catequentinib inn
- catequentinib usan
- catequentinib who dd
- ATC classification codes
- L01EX
- CAS registry numbers
- 1058156-90-3
- ChEMBL ID
- CHEMBL4303201
- InChIKey
- KSMZEXLVHXZPEF-UHFFFAOYSA-N
- PubChem compound IDs
- 25017411
- FDA ingredient codes (UNII)
- GKF8S4C432
- Status
- opinion
- Status date
- 23 Jul 2026
- Approved indications
- Treatment of synovial sarcoma or leiomyosarcoma.
- Product number
- EMEA/H/C/006317
- Authorisation holder
- CATS Consultants GmbH
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Leiomyosarcoma
- Sarcoma
European medicines record
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- Yes
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- catequentinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- fibroblast growth factor receptor 1
- Gene symbol
- FGFR1
- Protein identifier
- P11362
- Median affinity
- 7.7
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- fms related receptor tyrosine kinase 1
- Gene symbol
- FLT1
- Protein identifier
- P17948
- Median affinity
- 8.4
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- fms related receptor tyrosine kinase 4
- Gene symbol
- FLT4
- Protein identifier
- P35916
- Median affinity
- 9
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- kinase insert domain receptor
- Gene symbol
- KDR
- Protein identifier
- P35968
- Median affinity
- 7.35
- Affinity units
- pIC50
- Mechanism
- Platelet-derived growth factor receptor beta inhibitor
- Action type
- Inhibitor
- Target
- Platelet-derived growth factor receptor beta
- Protein identifier
- P09619
- Mechanism
- Stem cell growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Mast/stem cell growth factor receptor Kit
- Protein identifier
- P10721
- Mechanism
- Vascular endothelial growth factor receptor 2 inhibitor
- Action type
- Inhibitor
- Target
- Vascular endothelial growth factor receptor 2
- Protein identifier
- P35968
- Mechanism
- Vascular endothelial growth factor receptor 3 inhibitor
- Action type
- Inhibitor
- Target
- Vascular endothelial growth factor receptor 3
- Protein identifier
- P35916
- Mechanism
- Platelet-derived growth factor receptor beta inhibitor
- Action type
- Inhibitor
- Target
- Platelet-derived growth factor receptor beta
- Mechanism
- Stem cell growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Mast/stem cell growth factor receptor Kit
- Mechanism
- Vascular endothelial growth factor receptor 2 inhibitor
- Action type
- Inhibitor
- Target
- Vascular endothelial growth factor receptor 2
- Mechanism
- Vascular endothelial growth factor receptor 3 inhibitor
- Action type
- Inhibitor
- Target
- Vascular endothelial growth factor receptor 3
- Condition
- Sarcoma, Ewing
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000174
- Subject identifier
- D012512
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Pheochromocytoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000239
- Subject identifier
- D010673
- Condition
- Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000349
- Subject identifier
- D002292
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Leiomyosarcoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000564
- Subject identifier
- D007890
- Condition
- Adenocarcinoma of Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000571
- Subject identifier
- D000077192
- Condition
- Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Mesothelioma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000588
- Subject identifier
- D008654
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neuroblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Sarcoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000707
- Subject identifier
- D002294
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Lung Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001071
- Subject identifier
- D008175
- Condition
- Sarcoma, Synovial
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001376
- Subject identifier
- D013584
- Condition
- Multiple Myeloma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Thyroid Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002892
- Subject identifier
- D013964
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
And 36 more, listed on the interactive page.
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000239
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000564
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000638
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000681
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001071
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001376
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 1
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 1
- Condition identifier
- EFO_0002916
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003818
- Condition identifier
- EFO_0003820
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003841
And 124 more, listed on the interactive page.
- Event
- abdominal pain
- Reports
- 4
- Reporting signal score
- 7.38725
- Event
- alanine aminotransferase
- Reports
- 1
- Reporting signal score
- 6.90651
- Event
- alanine aminotransferase increased
- Reports
- 3
- Reporting signal score
- 7.26438
- Event
- anaemia
- Reports
- 8
- Reporting signal score
- 20.9632
- Event
- aspartate aminotransferase
- Reports
- 1
- Reporting signal score
- 6.74257
- Event
- aspartate aminotransferase increased
- Reports
- 3
- Reporting signal score
- 7.60775
- Event
- bronchial haemorrhage
- Reports
- 1
- Reporting signal score
- 6.6934
- Event
- decreased appetite
- Reports
- 6
- Reporting signal score
- 15.7581
- Event
- diarrhoea
- Reports
- 10
- Reporting signal score
- 20.7547
- Event
- disease progression
- Reports
- 4
- Reporting signal score
- 10.4908
- Event
- fatigue
- Reports
- 10
- Reporting signal score
- 20.1127
- Event
- haemoptysis
- Reports
- 3
- Reporting signal score
- 10.8672
- Event
- hepatic function abnormal
- Reports
- 3
- Reporting signal score
- 9.33834
- Event
- hyperbilirubinaemia
- Reports
- 4
- Reporting signal score
- 18.3771
- Event
- hypertension
- Reports
- 11
- Reporting signal score
- 35.3557
- Event
- hyperthyroidism
- Reports
- 2
- Reporting signal score
- 7.37952
- Event
- hypoalbuminaemia
- Reports
- 3
- Reporting signal score
- 13.955
- Event
- hypothyroidism
- Reports
- 7
- Reporting signal score
- 31.6726
- Event
- leukoderma
- Reports
- 1
- Reporting signal score
- 7.03295
- Event
- leukopenia
- Reports
- 7
- Reporting signal score
- 25.4426
- Event
- mouth ulceration
- Reports
- 2
- Reporting signal score
- 6.45358
- Event
- myelosuppression
- Reports
- 2
- Reporting signal score
- 7.62189
- Event
- nausea
- Reports
- 12
- Reporting signal score
- 25.6973
- Event
- nephritis
- Reports
- 2
- Reporting signal score
- 10.1826
- Event
- neutropenia
- Reports
- 8
- Reporting signal score
- 23.2232
And 8 more, listed on the interactive page.
- NCT01833923
- NCT01878448
- NCT02752516
- NCT02825563
- NCT04216082
- NCT04236362
- NCT05028504
- NCT01874873
- NCT02622932
- NCT03897283
- NCT03975036
- NCT05262335
- NCT01924195
- NCT02029209
- NCT02388919
- NCT03624309
- NCT03646968
- NCT03654027
- NCT03672136
- NCT03726736
- NCT03728374
- NCT03732001
- NCT03735264
- NCT03736837
- NCT03743129
And 176 more, listed on the interactive page.
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 82.39
- Calculated partition coefficient (ALogP)
- 4.83
- Calculated partition coefficient (XLogP)
- 3.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 30
- Molecular formula
- C23H22FN3O3
- Monoisotopic mass
- 407.16451973
- Natural product
- No
- Recorded assays
- 175
- Active assays
- 60
- Confirmatory
- Other
Related records
Trials (323)
- A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
- A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
- A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma
- A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
- A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.
- A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
- A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics
- A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
- A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
- A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
- A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
- A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer
- A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer
- A Phase II Study of Anlotinib in MTC Patients
- A Phase II Study of Anlotinib in STS Patients
- A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
- A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
- A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial
- A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
- A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.
In development for (63)
- Adrenal gland pheochromocytoma Phase 2
- Alveolar soft part sarcoma Phase 3
- Biliary tract cancer Phase 2
- Bone neoplasm Phase 2
- Brainstem cancer Phase 2
- Breast cancer Phase 2
- Breast neoplasm Phase 2
- Cancer Phase 2
- Carcinoma Phase 2
- Carcinoma of esophagus Phase 2
- Cervical cancer Phase 2
- Cholangiocarcinoma Phase 1
- Chronic graft versus host disease Phase 2
- Clear cell renal carcinoma Phase 2
- Colorectal cancer Phase 2
- Diffuse large B-cell lymphoma Phase 2
- Digestive system neuroendocrine neoplasm Phase 2
- Endometrial cancer Phase 2
- Endometrial carcinoma Phase 2
- Esophageal cancer Phase 2
Other linked conditions (6)
- Craniopharyngioma
- Fallopian tube cancer
- Liver cancer
- Neoplasm of esophagus
- Peritoneum cancer
- Thyroid tumor